open access

Ahead of print
Review Article
Published online: 2021-01-14
Get Citation

Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia

Stanisław Surma, Monika Romańczyk, Krzysztof J. Filipiak
DOI: 10.5603/CJ.a2021.0006
·
Pubmed: 33470417

open access

Ahead of print
Review articles
Published online: 2021-01-14

Abstract

Angiopoietin-like proteins (ANGPTL) are involved in the regulation of numerous physiological and biochemical processes. ANGPTL3, 4 and 8, which are involved in the regulation of lipoprotein metabolism, are particularly important. ANGPTL3, 4 and 8 have been shown to regulate triglyceride availability depending on the nutritional status of the body. In addition, a deficiency of these proteins has been found to cause hypolipidemia (reduction of all lipid fractions). Increases in ANGPTL3, 4 and 8 appear to be associated with cardiovascular risk. Animal studies indicate that the use of ANGPTL3 (evinacumab) inhibitors significantly reduces plasma total cholesterol, triglycerides and low-density lipoprotein concentrations. The use of evinacumab in clinical trials also led to the normalization of plasma lipid concentrations in patients with atherogenic dyslipidemia and homozygous familial hypercholesterolemia. The results of these studies indicate that evinacumab may in the future be used in the treatment of lipid disorders, especially those with hypertriglyceridemia.

Abstract

Angiopoietin-like proteins (ANGPTL) are involved in the regulation of numerous physiological and biochemical processes. ANGPTL3, 4 and 8, which are involved in the regulation of lipoprotein metabolism, are particularly important. ANGPTL3, 4 and 8 have been shown to regulate triglyceride availability depending on the nutritional status of the body. In addition, a deficiency of these proteins has been found to cause hypolipidemia (reduction of all lipid fractions). Increases in ANGPTL3, 4 and 8 appear to be associated with cardiovascular risk. Animal studies indicate that the use of ANGPTL3 (evinacumab) inhibitors significantly reduces plasma total cholesterol, triglycerides and low-density lipoprotein concentrations. The use of evinacumab in clinical trials also led to the normalization of plasma lipid concentrations in patients with atherogenic dyslipidemia and homozygous familial hypercholesterolemia. The results of these studies indicate that evinacumab may in the future be used in the treatment of lipid disorders, especially those with hypertriglyceridemia.

Get Citation

Keywords

angiopoietin-like proteins (ANGPTL), evinavumab, ANGPTL3-LRx, familial hypercholesterolemia

About this article
Title

Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Review Article

Published online

2021-01-14

DOI

10.5603/CJ.a2021.0006

Pubmed

33470417

Keywords

angiopoietin-like proteins (ANGPTL)
evinavumab
ANGPTL3-LRx
familial hypercholesterolemia

Authors

Stanisław Surma
Monika Romańczyk
Krzysztof J. Filipiak

References (47)
  1. Ruscica M, Zimetti F, Adorni MP, et al. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacol Res. 2020; 153: 104653.
  2. Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol (Lausanne). 2014; 5: 4.
  3. Tarugi P, Bertolini S, Calandra S. Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia. J Biomed Res. 2019; 33(2): 73–81.
  4. Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med. 2008; 18(1): 6–14.
  5. Lupo MG, Ferri N. Angiopoietin-lke 3 (ANGPTL3) and atherosclerosis: lipid and non-lipid related effects. J Cardiovasc Dev Dis. 2018; 5(3).
  6. Essalmani R, Susan-Resiga D, Chamberland A, et al. Furin is the primary in vivo convertase of angiopoietin-like 3 and endothelial lipase in hepatocytes. J Biol Chem. 2013; 288(37): 26410–26418.
  7. Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 2012; 109(48): 19751–19756.
  8. Haller JF, Mintah IJ, Shihanian LM, et al. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res. 2017; 58(6): 1166–1173.
  9. Kaplan R, Zhang T, Hernandez M, et al. Regulation of the angiopoietin-like protein 3 gene by LXR. J Lipid Res. 2003; 44(1): 136–143.
  10. Foka P, Karamichali E, Dalagiorgou G, et al. Hepatitis C virus modulates lipid regulatory factor Angiopoietin-like 3 gene expression by repressing HNF-1α activity. J Hepatol. 2014; 60(1): 30–38.
  11. Ortega-Senovilla H, Schaefer-Graf U, Meitzner K, et al. Decreased concentrations of the lipoprotein lipase inhibitor angiopoietin-like protein 4 and increased serum triacylglycerol are associated with increased neonatal fat mass in pregnant women with gestational diabetes mellitus. J Clin Endocrinol Metab. 2013; 98(8): 3430–3437.
  12. Nakajima K, Tokita Y, Tanaka A, et al. The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins. Clin Chim Acta. 2019; 495: 382–393.
  13. Olivecrona G. Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol. 2016; 27(3): 233–241.
  14. Shimizugawa T, Ono M, Shimamura M, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002; 277(37): 33742–33748.
  15. Yu JE, Han SY, Wolfson B, et al. The role of endothelial lipase in lipid metabolism, inflammation, and cancer. Histol Histopathol. 2018; 33(1): 1–10.
  16. Liu J, Afroza H, Rader DJ, et al. Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases. J Biol Chem. 2010; 285(36): 27561–27570.
  17. Mattijssen F, Kersten S. Regulation of triglyceride metabolism by Angiopoietin-like proteins. Biochim Biophys Acta. 2012; 1821(5): 782–789.
  18. Chi X, Shetty SK, Shows HW, et al. Angiopoietin-like 4 modifies the interactions between lipoprotein lipase and its endothelial cell transporter GPIHBP1. J Biol Chem. 2015; 290(19): 11865–11877.
  19. Haller JF, Mintah IJ, Shihanian LM, et al. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res. 2017; 58(6): 1166–1173.
  20. Kovrov O, Kristensen KK, Larsson E, et al. On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity. J Lipid Res. 2019; 60(4): 783–793.
  21. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med (Berl). 2002; 80(12): 753–769.
  22. Dijk W, Kersten S. Regulation of lipid metabolism by angiopoietin-like proteins. Curr Opin Lipidol. 2016; 27(3): 249–256.
  23. Aryal B, Price NL, Suarez Y, et al. ANGPTL4 in metabolic and cardiovascular disease. Trends Mol Med. 2019; 25(8): 723–734.
  24. Dang F, Wu R, Wang P, et al. Fasting and feeding signals control the oscillatory expression of ANGPTL8 to modulate lipid metabolism. Sci Rep. 2016; 6: 36926.
  25. Morinaga J, Zhao J, Endo M, et al. Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: A cross-sectional study. PLoS One. 2018; 13(3): e0193731.
  26. Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017; 377(3): 211–221.
  27. Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017; 69(16): 2054–2063.
  28. Koishi R, Ando Y, Ono M, et al. ANGPTL3 regulates lipid metabolism in mice. Nat Genet. 2002; 30(2): 151–157.
  29. Shimamura M, Matsuda M, Kobayashi S, et al. Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes. Biochem Biophys Res Commun. 2003; 301(2): 604–609.
  30. Shimamura M, Matsuda M, Yasumo H, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol. 2007; 27(2): 366–372.
  31. Fujimoto K, Koishi R, Shimizugawa T, et al. Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim. 2006; 55(1): 27–34.
  32. Wang Y, McNutt MC, Banfi S, et al. Hepatic ANGPTL3 regulates adipose tissue energy homeostasis. Proc Natl Acad Sci U S A. 2015; 112(37): 11630–11635.
  33. Strilchuk L, Fogacci F, Cicero AFg. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019; 18(7): 611–621.
  34. Pirillo A, Norata GD, Catapano AL. LDL-cholesterol-lowering therapy. Handb Exp Pharmacol. Springer, Berlin, Heidelberg. 2020 [Epub ahead of print].
  35. Wang Y, Gusarova V, Banfi S, et al. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015; 56(7): 1296–1307.
  36. Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015; 56(7): 1308–1317.
  37. Pouwer MG, Pieterman EJ, Worms N, et al. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. J Lipid Res. 2020; 61(3): 365–375.
  38. Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med. 2017; 377(3): 222–232.
  39. Chadwick AC, Evitt NH, Lv W, et al. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation. 2018; 137(9): 975–977.
  40. Desai U, Lee EC, Chung K, et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci U S A. 2007; 104(28): 11766–11771.
  41. Dewey FE, Gusarova V, O'Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016; 374(12): 1123–1133.
  42. Dunbar R, Bouzelmat A, Pordy G, et al. Abstract 19133: Inhibition of ANGPTL3 by Evinacumab Reduced Triglycerides (TGs) and LDL-C in Subjects Presenting With Modest Elevations in TGs and/or LDL-C, Recapitulating the Hypolipidemic Effects of Loss-of-Function (LoF) Mutations of ANGPTL3. Circulation. 2016; 134: A19133.
  43. Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019; 140(6): 470–486.
  44. Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N Engl J Med. 2017; 377(3): 296–297.
  45. Hovingh GK, Gipe DA, Ahmad Z, et al. Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies. Abstract 5938. Eur Heart J. 2017; 38(suppl_1).
  46. Banerjee P, Chan KC, Tarabocchia M, et al. Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. Arterioscler Thromb Vasc Biol. 2019; 39(11): 2248–2260.
  47. Raal F. Evinacumab in patients with homozygous familial hypercholesterolemia. Presented on: March 30. 2020: ACC 2020.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl